Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells

References

• Alizadeh A, Eisen M, Davis R, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Therapy for diffuse large B-cell lymphoma: getting personal. Lancet 2013;6736:1–2.
   Google Scholar
• Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14:309–317.
   PubMed Web of Science ®Google Scholar
• Korycka-Wołowiec A, Robak T. Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies. Expert Opin Drug Metab Toxicol 2012;8:1455–1468.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203–1210.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204–210.
   PubMed Web of Science ®Google Scholar
• Sanchez-Gonzalez B, Garcia M, Serrano S, et al. Bendamustine-containing immunochemotherapy is active in transformed follicular lymphoma with overexpression of p53. Leuk Lymphoma 2009; 50:455–456.
   PubMed Web of Science ®Google Scholar
• Walter E, Schmitt T, Dietrich S, et al. Rituximab and bendamustine in patients with CD20 + diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. Leuk Lymphoma 2012;53:2290–2292.
   PubMed Web of Science ®Google Scholar
• Ohmachi K, Niitsu N, Uchida T, et al. Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol 2013;31:2103–2109.
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769–784.
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12:1247–1252.
   PubMed Web of Science ®Google Scholar
• Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:1198–1203.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Mitsiades CS, Laubach JP, et al. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res 2013;37:829–837.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006;24:166–173.
   PubMed Web of Science ®Google Scholar
• Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008;19:964–969.
   PubMed Web of Science ®Google Scholar
• Dasmahapatra G, Lembersky D, Kramer L, et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 2010;115:4478–4487.
   PubMed Web of Science ®Google Scholar
• Zuco V, De Cesare M, Cincinelli R, et al. Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo. PLoS One 2011;6:e29085.
   PubMed Web of Science ®Google Scholar
• Bodo J, Zhao X, Sharma A, et al. The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways. Br J Haematol 2013;163:72–80.
   PubMed Web of Science ®Google Scholar
• Hagiwara K, Kunishima S, Iida H, et al. The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line. Apoptosis 2015;20:975–985.
   PubMed Web of Science ®Google Scholar
• Chen R, Frankel P, Popplewell L, et al. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica 2015; 100:357–362.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2012;120:3986–3996.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275–282.
   PubMed Web of Science ®Google Scholar
• Bliss CI. The toxicity of poisons applied jointly. Ann Appl Biol 1939;26:585–615.
   Google Scholar
• Wilson WH. Treatment strategies for aggressive lymphomas: what works? Hematol Am Soc Hematol Educ Program 2013;2013:584–590.
   PubMedGoogle Scholar
• Weidmann E, Kim S-Z, Rost A, et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1285–1289.
   PubMed Web of Science ®Google Scholar
• Vacirca JL, Acs PI, Tabbara IA, et al. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol 2013;93:403–409.
   PubMed Web of Science ®Google Scholar
• Kaneko N, Mitsuoka K, Amino N, et al. Combination of YM155, a Survivin suppressant, with Bendamustine and Rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell Lymphoma. Clin Cancer Res 2014;20:1814–1822.
   PubMed Web of Science ®Google Scholar
• Beeharry N, Rattner JB, Bellacosa A, et al. Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustine. PLoS One 2013;7:e40342.
   Web of Science ®Google Scholar
• Sakajiri S, Kumagai T, Kawamata N, et al. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 2005;33:53–61.
   PubMed Web of Science ®Google Scholar
• Cai Y, Cui W, Chen W, et al. The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms. Cancer Cell Int 2013;13:1–9.
   PubMed Web of Science ®Google Scholar
• Thompson RC, Vardinogiannis I, Gilmore TD. The sensitivity of diffuse large B-Cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity. PLoS One 2013;8:e62822.
   PubMed Web of Science ®Google Scholar
• Tula-Sanchez AA, Havas AP, Alonge PJ, et al. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: role of cyclin-dependent kinase inhibitors. Cancer Biol Ther 2013;14:949–961.
   PubMed Web of Science ®Google Scholar
• Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861–1874.
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541–5552.
   PubMed Web of Science ®Google Scholar
• Mah L-J, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010; 24:679–686.
   PubMed Web of Science ®Google Scholar
• Kim MS, Blake M, Baek JH, et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003;63:7291–7300.
   PubMed Web of Science ®Google Scholar
• Blagosklonny M V, Trostel S, Kayastha G, et al. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res 2005;65:7386–7392.
   PubMed Web of Science ®Google Scholar
• Marchion DC, Bicaku E, Daud AI, et al. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 2004; 92:223–237.
   PubMed Web of Science ®Google Scholar
• Ageberg M, Rydström K, Relander T, et al. The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death. Am J Transl Res 2013;5:170–183.
   PubMed Web of Science ®Google Scholar
• Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, et al. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 2006;108:1174–1182.
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Kikuchi J, Koyama D, et al. Alkylating agents induce histone H3K18 hyperacetylation and potentiate HDAC inhibitor-mediated global histone acetylation and cytotoxicity in mantle cell lymphoma. Blood Cancer J 2013;3:e169.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476:298–303.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Hatzi K, Shaknovich R. Mechanisms of epigenetic deregulation in lymphoid neoplasms. Blood 2013;121:4271–4279.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Dalla-Favera R. SnapShot: diffuse large B cell lymphoma. Cancer Cell 2014;25:132–132.e1.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011;471:189–195.
   PubMed Web of Science ®Google Scholar
• Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004;432:635–639.
   PubMed Web of Science ®Google Scholar
• Garbati MR, Alço G, Gilmore TD. Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8. Cancer Lett 2010;291:237–245.
   PubMed Web of Science ®Google Scholar
• Vousden KH, Lane DP. P53 in health and disease. Nat Rev Mol Cell Biol 2007;8:275–283.
   PubMed Web of Science ®Google Scholar
• Roué G, López-Guerra M, Milpied P, et al. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 2008;14:6907–6915.
   PubMed Web of Science ®Google Scholar
• Yan W, Liu S, Xu E, et al. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene 2013; 32:599–609.
   PubMed Web of Science ®Google Scholar
• Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000;97:10014–10019.
   PubMed Web of Science ®Google Scholar
• Inoue S, Riley J, Gant TW, et al. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 2007;21:1773–1782.
   PubMed Web of Science ®Google Scholar
• Henderson C, Mizzau M, Paroni G, et al. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 2003;278:12579–12589.
   PubMed Web of Science ®Google Scholar
• Hajji N, Wallenborg K, Vlachos P, et al. Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells. Oncogene 2008;27:3134–3144.
   PubMed Web of Science ®Google Scholar